Formation of an internal FDA Nanotechnology Task Force

	Tweet

Acting Commissioner of Food and Drugs Andrew C. von Eschenbach, M.D., today announced the formation of an internal FDA Nanotechnology Task Force.

The new task force is charged with determining regulatory approaches that encourage the continued development of innovative, safe and effective FDA-regulated products that use nanotechnology materials.

The task force will identify and recommend ways to address any knowledge or policy gaps that exist so as to better enable the agency to evaluate possible adverse health effects from FDA-regulated products that use nanotechnology materials. FDA will continue to address product-specific nanotechnology-related issues on an ongoing basis.

"As this exciting new area of science develops, FDA must be positioned to address both health promotion and protection challenges that it may present,” said Dr. von Eschenbach. “Through this task force, we are leveraging our expertise and resources to guide the science and technology in the development of nanotechnology-based applications.”

Specifically, the task force will:

• Chair a public meeting to help FDA further its understanding of developments in nanotechnology materials that pertain to FDA-regulated products, including new and emerging scientific issues such as those pertaining to biological interactions that may lead to either beneficial or adverse health effects. This public meeting is scheduled for October 10.
  
• Assess the current state of scientific knowledge pertaining to nanotechnology materials for purposes of carrying out FDA’s mission.
  
• Evaluate the effectiveness of the agency’s regulatory approaches and authorities to meet any unique challenge that may be presented by the use of nanotechnology materials in FDA-regulated products.
  
• Explore opportunities to foster innovation using nanotechnology materials to develop safe and effective drugs, biologics and devices, and to develop safe foods, feeds, and cosmetics.
  
• Continue to strengthen FDA’s collaborative relationships with other federal agencies, including the agencies participating in the National Nanotechnology Initiative such as the National Institutes of Health (NIH), the Environmental Protection Agency (EPA), and the United States Department of Agriculture (USDA), as well as with foreign government regulatory bodies, international organizations, healthcare professionals, industry, consumers, and other stakeholders to gather information regarding nanotechnology materials used or that could be used in FDA-regulated products.
  
• Consider appropriate vehicles for communicating with the public about the use of nanotechnology materials in FDA-regulated products.
  
• Submit its initial findings and recommendations to the Acting Commissioner within nine months of the public meeting.

The National Nanotechnology Initiative (a United States government research and development coordinating program,) refers to nanotechnology as “the understanding and control of matter at dimensions of roughly 1 to 100 nanometers, where unique phenomena enable novel applications.” A nanometer is a billionth of a meter. A human hair is about 80,000 nanometers in width.

Materials made in the nanoscale size range can often have chemical or physical properties that are different from those of their larger counterparts. Such differences include altered magnetic properties, altered electrical or optical activity, increased structural integrity, and increased chemical and biological activity. Because of these properties, nanotechnology materials have great potential for use in a vast array of products. Also because of some of their special properties, they may pose different safety issues than their larger counterparts.

http://www.fda.gov/OHRMS/DOCKETS/98fr/06n-0107-nm00002.pdf

RELATED STORIES:
Ibuprofen curbs aspirin’s anti-clotting action   FDA sends user-fee recommendations to Congress   ‘Me-too’ prescription drugs win support in Tufts study   Tamiflu still choice for bird flu, pandemic - WHO   Glaxo braves fire over HIV drug trials in orphans   Pfizer Endometriosis Pain Drug Gets OK’d   US advises firms on better drug safety monitoring   Merck says poor health, not Vioxx, caused attacks   Powerful pain medicine a growing U.S. crime problem   New group B strep test for newborn babies approved   Novartis says leukemia drug helps when Gleevec fails   Short antibiotic course effective in COPD flare-ups

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]